Director Gregg Williams of Vivani Medical, Inc. (NASDAQ: VANI) executed two insider purchases on March 15, 2026, acquiring common shares with a combined value of approximately $1.68 million.
The first transaction consisted of 1,310,680 shares bought at $1.03 per share, for a total of $1,350,000. A separate purchase comprised 264,551 shares at $1.26 per share, valued at $333,334. Together these trades sum to roughly $1.68 million in aggregate consideration.
At the time of the trades, Vivani’s stock was trading near $1.10 and the company’s market capitalization was reported at $87.84 million. Third-party market indicators cited in company-related commentary show mixed signals: an RSI reading that suggests the shares may be in oversold territory, while an InvestingPro assessment referenced by market commentary indicates the stock is currently trading above its calculated Fair Value.
Following the March 15 transactions, Gregg Williams’ total direct and indirect holdings in Vivani amount to 36,156,383 shares. That ownership aggregate includes shares held directly and interests held through entities and trusts identified as Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and Sam B. Williams 1995 Generation-Skipping Trust.
These insider purchases coincide with recent corporate financing activity. Vivani announced the closing of a registered direct offering and a private placement that together generated approximately $4.5 million in gross proceeds. The financing was executed through the sale of 1,689,200 shares of common stock at $1.48 per share.
Gregg Williams, who serves as Chairman of Vivani’s board of directors, also participated in the private placement tranche, acquiring 1,351,351 shares at $1.48 per share. Company statements indicated the proceeds from the securities offering are intended to support ongoing research efforts.
On the clinical front, Cortigent, a wholly owned subsidiary of Vivani Medical, reported completion of a six-year Early Feasibility Study for the Orion Visual Cortical Prosthesis System. According to the company, the study demonstrated the system’s safety and efficacy in producing visual perception for blind individuals. Results from the feasibility study were presented at the North American Neuromodulation Society annual meeting.
Collectively, the insider purchases, the capital raise, and the clinical-study results represent concurrent developments for Vivani that touch both its corporate funding profile and its product-development progress. The financing provides additional capital earmarked for research, while the feasibility study results were positioned as evidence of the technology’s clinical performance over a multi-year evaluation period.
Readers should note the reporting on market indicators and Fair Value came from InvestingPro analyses cited alongside the company’s transaction disclosures and financing announcements. The ownership totals reflect direct and indirect holdings disclosed by Gregg Williams through the aforementioned trusts and entities.
This reporting is based on disclosed insider transactions, financing close figures, and company statements regarding a completed feasibility study. No projections or additional claims beyond those disclosed by the company and the referenced market analyses have been introduced.